Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
trastuzumab + ST-PHPMA
- Development stage
- Preclinical
- Lead developer
- University of Maryland College Park
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
trastuzumab + ST-PHPMA is an antibody-polymer conjugate consisting of the HER2-targeting monoclonal antibody trastuzumab covalently conjugated to a semitelechelic poly[N-(2-hydroxypropyl)methacrylamide] (ST-PHPMA) copolymer backbone. Developed by researchers at the University of Maryland, this macromolecular drug delivery system is designed to actively target HER2-overexpressing cancer cells, such as those in HER2-positive breast cancer. By utilizing a semitelechelic polymer structure, the conjugate allows for single-point attachment to the antibody, avoiding cross-linking and maintaining the antibody's bioactivity. In preclinical studies, the conjugate demonstrated prolonged inhibitory effects on the MAPK and Akt signaling pathways compared to free trastuzumab, suggesting that polymer conjugation can extend the therapeutic activity of the antibody while retaining its efficacy.
- Other names
- ST-PHPMA-trastuzumab conjugateT/STP 1/1TRZ-ST-PHPMAtrastuzumab-ST-PHPMA conjugate
02
Targets
ERBB2 (Erb-b2 receptor tyrosine kinase 2)
Beyond the preview
Go deeper on trastuzumab + ST-PHPMA.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on trastuzumab + ST-PHPMA.